News

The Korea Fund, Inc. Announces Significant Cash Dividend

The Korea Fund, Inc. Announces Significant Cash Dividend

The Korea Fund Declares Dividend Distribution

The Korea Fund, Inc. (NYSE:KF) recently made an important announcement regarding its dividend distribution. The Fund's Board of Directors has declared a cash dividend of $0.454161 per share. This decision reflects the Fund's commitment to providing returns to its shareholders and signifies the ongoing performance of its investment portfolio.

Details of the Dividend Distribution

This dividend represents a payment as part of the Fund's spillback distribution for the following fiscal year, based on provisions in the Internal Revenue Code. Shareholders can expect to receive this distribution starting January 6, 2025, to those who were on record as of the ex-dividend date on December 23, 2024.

Impact on Share Repurchase Program

As part of this dividend announcement, the Fund has decided to temporarily suspend its share repurchase program until the dividend payment date. This decision aligns with the Fund's strategic focus on maximizing shareholder value while ensuring a stable financial position for future investments.

Tax Characterization Factors

While the overall distribution amount remains unchanged, the characterization for tax purposes may differ due to the nature of the Fund's investments. Factors such as investment performance and the types of securities held will influence this characterization. Shareholders will receive a Form 1099-DIV after the payment date, detailing how the distribution should be reported on their tax returns.

Investment Strategy of The Korea Fund

The Korea Fund, Inc. takes pride in its investment strategy focused on capital appreciation. The Fund primarily invests in equity securities listed on Korean stock exchanges, catering to investors looking for long-term growth. With its shares traded on the New York Stock Exchange under the ticker symbol “KF,” the Fund aims to navigate the complexities of international investments to offer viable returns.

Advisory and Market Risks

JPMorgan Asset Management (Asia Pacific) Ltd serves as the Fund's Investment Adviser, providing expertise to manage its investment portfolio. However, it's essential to remember that investing in closed-end funds carries inherent risks. These risks include fluctuations in currency value, shifting government regulations, and economic changes, all of which may increase the overall volatility of the Fund's investments.

Volatility and Investment Framework

The value of securities in which the Fund invests can exhibit significant price variations, particularly in foreign markets. This factor underscores the importance of understanding market dynamics, as closed-end funds typically trade at market value, which may differ from their net asset value (NAV). Investors should stay informed about the daily NAV and market prices to make educated decisions.

Market Information Accessibility

For those interested in tracking the Fund's performance, daily data regarding the NYSE closing market price, NAV, and additional statistics are available through The Korea Fund's official website. Shareholders can also contact their stockholder servicing agent for personalized support related to their investments.

Investment Considerations

This announcement does not serve as a recommendation to buy or sell specific securities. Investors should approach investment decisions cautiously, utilizing credible information sources and seeking professional advice. Past performance, while informative, does not guarantee future results for The Korea Fund, Inc.

Investors should be aware that shares of the Fund are not FDIC-insured and involve investment risks, including the possibility of losing principal. Understanding these elements is crucial for navigating the landscape of investments in closed-end funds.

Frequently Asked Questions

What is the dividend amount declared by The Korea Fund, Inc.?

The Korea Fund, Inc. has declared a cash dividend of $0.454161 per share.

When will the dividend be paid to shareholders?

The dividend will be payable on January 6, 2025, to shareholders on record as of December 23, 2024.

How does the dividend affect the share repurchase program?

The Fund has temporarily suspended its share repurchase program until after the dividend payment.

What factors influence the tax characterization of the distribution?

The characterization can be influenced by the performance of the Fund's investments and the type of securities held.

How can I find out more about the Fund's performance?

Investors can visit The Korea Fund’s website for updated daily market prices, NAV, and other relevant information.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles